<DOC>
	<DOC>NCT00387972</DOC>
	<brief_summary>GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo, taken once daily in patients with Type 2 diabetes mellitus.</brief_summary>
	<brief_title>Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria: Type 2 diabetes mellitus treated with diet and exercise or oral antidiabetic treatment Body mass index between 20 and 40 Females of childbearing potential must use adequate birth control. Exclusion criteria: Subjects with previous use of insulin Type 1 diabetes Uncontrolled thyroid disease History of drug or alcohol abuse in the past year Any other clinically significant disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Type 2 diabetes mellitus (T2DM)</keyword>
	<keyword>glycosylated hemoglobin (HbA1c)</keyword>
	<keyword>denagliptin</keyword>
	<keyword>diabetes treatment</keyword>
	<keyword>glycemic control</keyword>
</DOC>